Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [12612]

ASCO 2015: Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

ASCO 2015: Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

ASCO 2015: Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

ASCO 2015: Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

ASCO 2015: Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

Alarm bells are ringing for patients in england says bowel cancer UK

Alarm bells are ringing for patients in england says bowel cancer UK

Increasing body mass index linked with worse localised prostate cancer outcomes

Increasing body mass index linked with worse localised prostate cancer outcomes

Lower cancer survival in UK linked to delays in referring patients for tests

Lower cancer survival in UK linked to delays in referring patients for tests

How ovarian cancers evade chemotherapy

How ovarian cancers evade chemotherapy

ASCO 2015: Adding chemotherapy to initial therapy extends lives of men with advanced, hormone-naïve prostate cancer

ASCO 2015: Adding chemotherapy to initial therapy extends lives of men with advanced, hormone-naïve prostate cancer

ASCO 2015: Augmenting standard therapies increases cure rates for high-risk wilms tumour

ASCO 2015: Augmenting standard therapies increases cure rates for high-risk wilms tumour

More from ecancer